Table 3 Previous therapies and course of 13 patients with grade ≥ 3 hematologic adverse events
Patient | Previous therapies | Toxicity (CTCmax) | Reversibility | Time to toxicity (weeks) | Time to reversibility (weeks) | Course of treatment/disease | ||
|---|---|---|---|---|---|---|---|---|
Hb | WBC | Platelets | ||||||
1 | RP, Rx, ADT, DOCE, ABI, CABA | 3 | 3 | 3 | Yes | 8 | 12 | Recovery after transfusion (2xRBC) |
2 | ADT, DOCE, Ra-223 | 3 | 1 | 0 | Yes | 4 | 4 | Recovery after transfusion (2xRBC) |
3 | ADT, local Rx | 3 | 2 | 0 | Yes | 4 | 6 | Transfusion therapy, disease progression, death 18 months after PSMA therapy |
4 | RP, ADT, DOCE, ENZA | 2 | 1 | 3 | – | 8 | – | Lost to follow-up |
5 | ADT, bicalutamide, ABI, DOCE, Rx | 3 | 0 | 0 | Yes | 6 | 4 | Spontaneous recovery, discontinuation of RLT due to PD, continuation of ABI |
6 | ADT, ABI, Rx, DOCE, bicalutamide, ENZA | 3 | 3 | 3 | Yes | 8 | 8 | Recovery of all cell lines after 4xRBC, diagnosed with NSCLC after PR under RLT |
7 | RARP, Rx, ADT, ABSI, DOCE, ENZA | 3 | 1 | 0 | Yes | 4 | 6 | Continuation of RLT after transfusion (2xRBC) |
8 | ADT, bicalutamide, Ra-223 | 3 | 2 | 1 | Yes | 8 | 4 | Carbamazepin intoxication, discontinuation of RLT, spontaneous recovery |
9 | ADT, palliative Rx, ABI, ENZA, DOCE, CABA, 5-FU | 1 | 1 | 3 | Yes | 3 | 6 | Continuation of RLT after spontaneous recovery of platelet count, 3 more cycles, PD |
10 | RP, ADT, DOCE, ABI, ENZA | 3 | 2 | 1 | Yes | 8 | 8 | Continuation of RLT after transfusion (2xRBC) |
11 | RP, salvage Rx, ADT, DOCE, Ra-223, ABI | 3 | 3 | 2 | Yes | 4 | 12 | Transfusion therapy in 4 week intervals (2 × 2 RBC) |
12 | RARP, Rx, ADT, DOCE, ABI, CABA, carboplatin, etoposid, mitoxandrone, 5-FU | 1 | 3 | 3 | No | 8 | – | Transfusion of thrombocytes (2xBP), hepatic disease progression |
13 | RP, salvage Rx, ADT, Ra-223, ABI | 3 | 0 | 4 | No | 7 | – | Transfusion (RBC, BP) disease progression, death 8 weeks after last cycle |